HK1202433A1 - Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases - Google Patents

Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases Download PDF

Info

Publication number
HK1202433A1
HK1202433A1 HK15103021.0A HK15103021A HK1202433A1 HK 1202433 A1 HK1202433 A1 HK 1202433A1 HK 15103021 A HK15103021 A HK 15103021A HK 1202433 A1 HK1202433 A1 HK 1202433A1
Authority
HK
Hong Kong
Prior art keywords
natriuretic peptide
diseases
derivatives
cnp
anp
Prior art date
Application number
HK15103021.0A
Other languages
English (en)
Chinese (zh)
Inventor
Michael Kozlowski
Original Assignee
Kalos Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalos Therapeutics, Inc. filed Critical Kalos Therapeutics, Inc.
Publication of HK1202433A1 publication Critical patent/HK1202433A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15103021.0A 2011-12-16 2012-12-17 Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases HK1202433A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161576720P 2011-12-16 2011-12-16
US201161576720P 2011-12-16
PCT/US2012/070190 WO2013090931A2 (en) 2011-12-16 2012-12-17 Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases

Publications (1)

Publication Number Publication Date
HK1202433A1 true HK1202433A1 (en) 2015-10-02

Family

ID=48613379

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103021.0A HK1202433A1 (en) 2011-12-16 2012-12-17 Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases

Country Status (7)

Country Link
US (1) US20150045301A1 (enExample)
EP (1) EP2790714A4 (enExample)
JP (2) JP2015502368A (enExample)
CN (2) CN108653715A (enExample)
CA (1) CA2853204A1 (enExample)
HK (1) HK1202433A1 (enExample)
WO (1) WO2013090931A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106822182A (zh) * 2016-12-27 2017-06-13 广州姿生生物科技有限公司 一种细胞提取物及其用途
US11419917B2 (en) 2020-04-07 2022-08-23 Drora Shevy Treatment for SARS-CoV-2 and other coronaviruses

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
JPH10273450A (ja) * 1997-03-27 1998-10-13 Toagosei Co Ltd 眼内血管新生性疾患治療薬
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
WO2005094420A2 (en) * 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US20070049251A1 (en) 2005-08-31 2007-03-01 Mock Von A Method and system for wireless communication in emergency situations
JP5395794B2 (ja) * 2007-09-11 2014-01-22 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのガラニンペプチドの使用
KR20100057641A (ko) * 2007-09-11 2010-05-31 몬도바이오테크 래보래토리즈 아게 인터메딘 ４７ 및 ５３ 펩티드의 치료적 용도
KR20100057050A (ko) * 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 데슬로렐린 및 마스토파란의 용도
WO2009040006A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Spantide for therapeutic uses
EP2224946B1 (en) * 2007-12-28 2016-11-02 Kalos Therapeutics, Inc. Anti-proliferative compounds and their use
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
UY32902A (es) * 2009-09-25 2011-02-28 Alcon Res Ltd Nuevos agonistas de npr-b
WO2011075471A2 (en) * 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders

Also Published As

Publication number Publication date
EP2790714A4 (en) 2015-08-05
CN104039341A (zh) 2014-09-10
US20150045301A1 (en) 2015-02-12
JP2015502368A (ja) 2015-01-22
JP2018024674A (ja) 2018-02-15
EP2790714A2 (en) 2014-10-22
WO2013090931A2 (en) 2013-06-20
CA2853204A1 (en) 2013-06-20
CN108653715A (zh) 2018-10-16
WO2013090931A3 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
MX2023002973A (es) Uso de variantes de peptido natriuretico de tipo c para tratar displasia esqueletica.
WO2012145665A3 (en) Method of drug delivery for pth, pthrp and related peptides
WO2010135541A3 (en) Variants of c-type natriuretic peptide
HK1202800A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
WO2014091316A3 (en) Glucagon/glp-1 agonists for the treatment of obesity
IL262522B (en) Medicinal peptides of neuregulin for the treatment or prevention of heart failure
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
WO2012020307A3 (en) Therapeutic uses of microvesicles and related micrornas
PH12015501271B1 (en) Stabilized insulin-like growth factor polypeptides
WO2017100400A3 (en) Use of c-type natriuretic peptide variants to treat osteoarthritis
NZ630536A (en) Therapeutic agent or prophylactic agent for dementia
WO2012156968A3 (en) Use of mesenchymal stem cells for the improvement of affective and cognitive function
SG11201912195TA (en) Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies
WO2014057484A8 (en) Peptides for the treatment of neurodegenerative diseases
HK1256033A1 (zh) 用於刺激免疫系统的肽
EP4400164A3 (en) A method of inducing cardiomyocytes proliferation and treating heart diseases
PH12015501870A1 (en) Nutritional compositions contaqining a peptide component with adiponectin stimulating properties
EA033145B1 (ru) Применение полученных из pedf пептидов в стимуляции регенерации мышцы, регенерации сухожилия или артериогенеза
EP3491006A4 (en) PROCESS FOR THE PREPARATION OF PROTEINS OR PEPTIDES
WO2014036524A3 (en) Genetically modified msc and therapeutic methods
WO2012174488A3 (en) Agents and methods for treating ischemic and other diseases
WO2013051938A3 (en) Cyclic analogs of glp-1 and glp-1 related peptides and uses thereof
WO2011123858A3 (en) Ccn3 peptides and analogs thereof for therapeutic use
WO2013090931A3 (en) Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases